Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.68 |
| ▸ | BCL2 | P10415 | 8/20 | 0.52 |
| ▸ | BID | P55957 | 7/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 7/20 | 0.46 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751677 | 0.85 | BCL2L1 (0.51) | BCL2L1BCL2 | |
| SCHEMBL2972697 | 0.83 | BCL2L1 (0.85) | BCL2L1BCL2BIDBCL2A1 | |
| Oxalic Acid SCHEMBL29832219 | 0.82 | BCL2L1 (0.82) | BCL2L1BCL2BIDBCL2A1 | |
| SCHEMBL1567421 | 0.81 | BCL2L1 (1.00) | BCL2L1BCL2BIDBCL2A1 | |
| SCHEMBL1955370 | 0.81 | BCL2L1 (0.66) | BCL2L1BCL2BIDBCL2A1ADORA1 | |
| SCHEMBL1958566 | 0.80 | BCL2 (0.61) | BCL2 | |
| SCHEMBL21751620 | 0.80 | BCL2 (0.48) | BCL2L1BCL2 | |
| SCHEMBL1956837 | 0.79 | BCL2 (0.63) | BCL2L1BCL2 | |
| SCHEMBL25712911 | 0.79 | BCL2L1 (0.81) | BCL2L1BCL2BIDBCL2A1BAK1 | |
| SCHEMBL29402573 | 0.79 | BCL2L1 (0.66) | BCL2L1BCL2BIDBCL2A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2L1 4/4885BCL2 1/4885BID 22/4885 |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2L1 4/4885BCL2 1/4885BID 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.